Cumberland 10-Q: $80.6M Cash After Apotex Deal, Continuing Ops Still Burning $1.9M a Quarter
CPIX has more than doubled off its 52-week low of $1.85.
Summary
Cumberland's first full post-divestiture quarter shows $80.6 million of cash and $70.2 million of working capital, funded by the $100 million Apotex sale, while continuing operations lost $1.9 million. The $77.8 million net income is almost entirely the $81.1 million one-time disposal gain.
Key Events · Earnings and Guidance · CPIX
-
Q3 Net Income Is a Disposal Gain
Net income of $77.8 million for Q3 2026 includes an $81.1 million pre-tax gain on the July 1, 2026 Apotex closing; continuing operations lost $1.1 million after tax.
-
Cash Jumps to $80.6 Million
Cash and equivalents rose to $80,581,021 from $11,444,693 at December 31, 2025, and working capital reached $70.2 million versus $0.3 million, after the $22.5 million special dividend and $5.2 million credit-line repayment.
-
Continuing Ops Burn $1.9M a Quarter
Operating loss from continuing operations was $1,936,482 in Q3 and $8,104,724 for the nine months, with R&D at $841,162 and G&A at $2,182,285 for the quarter.
-
TSA Revenue Expires in 12 Months
Transition services revenue of $1,950,000 in Q3 comes from a 12-month Apotex agreement ($150,000 monthly administrative plus $500,000 monthly marketing fees) with one six-month renewal option.
Analysis · CPIX · Life Sciences
The headline $77.8 million net income is an accounting event, not an operating one: $81.1 million of it is the one-time gain on selling the commercial product portfolio to Apotex, and continuing operations actually lost $1.9 million in the quarter. What matters is the balance sheet — $80.6 million of cash and $70.2 million of working capital after paying a $22.5 million special dividend and retiring the $5.2 million credit line. That funds the ifetroban DMD NDA work and the rest of the pipeline for years without needing to sell stock, which is the real change from the cash-starved company of a year ago. The offset is that the only recurring revenue now is a $1.95 million-a-quarter transition services fee from Apotex that expires in twelve months, so the burn rate becomes the whole story once that runs off.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CPIX was trading at $5.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $88.1M. The 52-week trading range was $1.85 to $9.28. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.